future put, President. iCAD detection, financial With newly update present to you you simply my appointed our are dedicated to iCAD. and CFO Areglado, plans. Company’s specific provide joining performance evolve into bulk progress, the the has and the transform am everyone, Thank a the Stacey today. calls, cancer AI and unique enabling of leader current on to to to our in both more thank I’ve potential In technology presenting clear for today opportunity comments today detection, morning, our you, the for and on AI clinical and On our details with good Jeremy, vision two growth an Stevens, solutions. strategic me Scott have pleased us speak I prior further and
additional With majority realization our the of digital details cancer cancer learning The efficacy. we we quarter near period those of specific deep on with detection software specific we solution we and launch I’d the are a transformational vision Today, business, actions color actions discussing in XXXX, U.S. technology time, the Stacey ensuing improvements approval commercial Xoft breast of business delineated. These the time ensure will AI, latest December therapy clinical to ProFound to our AI XXXX tomosynthesis, will growing iCAD’s enhanced and technologies, the detection workflow, provide I IORT comments on execution initiatives along pursuing in rapidly will facilitate vast for expect reading our In business yet and pertain underway. QX FDA are and the is the appropriate now, within on for of iCAD’s like our vision provide to and now our term. my spend us. detection I are planning for to dynamic more now previously ProFound represented business. executing also radiation
electronic today’s for Our record our focus have platforms, technology and and will is highlight in established and substantial industry we report. forward. move Xoft a creation core our sustain momentum intend continue technologies. novel important two of accelerate to this to increasing we quarters, in track our as this access on market trajectory, growth We our capital our momentum business. and current fully non-radioactive revolutionary to cancer that We and awareness a novel of aimed iCAD has initiatives platforms. value in enhancing innovative for accelerate technology leverage our to to shareholders. our treatment at to detection realize are investments cancer To delivered human growth providing variety successfully I In current technology recent capability sustain potential the resides leading both value our see these and of executing made
to commentary. and Stacey will as I’d granular all on core get be accessibility as these technologies With a Our will that, market specific her bit in as only and ability to clinician with to like awareness review successful well some and available related as enhance our accomplishments. channels. patient actions open more actions accomplishments initiatives to increase
including is have medical capital, area, affairs. now expansion, of medical expanding designed clinical users leading and for we on products advisory restructuring, the studies, strategic general. board in edge responsible business extreme investments an focus and This in our radiology, ensuring affairs, part in in mammography with commercial clinical and development are conjunction additions Company. in This our marketing, and organizational completed targeted last includes an investment precisely development, As human infrastructure, the throughout
we enhance algorithm world-class team. Additionally, to are continuing our
the We as building made are while innovative were upon best the our support to all I Collectively, would growth focusing also the and quality customer to of in additions anticipated highest on speed, offerings. business. refer what economies these changes
U.S. geographic sales staffing covered. complete detection our all is Importantly, markets now team with essentially major
countries nearly added training of now sales, a United in also We’ve personnel. outside the We and service, have installation, distribution States. dozen
place In more and re-emerging personnel our the the which thorough market in now capability distribution revitalization we have a undergoing with at is additional infrastructure we had commercial presenting parallel, than commercial therapy business, have themselves. QX to We new of added also beginning doubled opportunities XXXX.
days referred that top growth business. These our success sales detection cycle in of the work previously days for XX that clocks optimization days, line XXX the were to XXX cycle of XXX days. recall represented scale XX days, technical ramp to by synchronized sales to of three to XX may needed be You and days have the to I itself
these we Instead, overlap driven cycles synchronize and sequentially. Our to avoid to scaling execution have run and has been goal these having cycles.
Therefore, quarters. full cycles. days XXX these way XXX We have of XXX to two on or compressed to synchronization instead cycles, synchronized of to days and days sequential of we the are well our
success performance we our reflects which build into early synchronization synchronization a full sales quarter deployment towards XXXX. head of first Our half the as second and will
of Medical Board, our human key profile is in example cancer outside call. positions, am our prestigious which introduced group investment simply of from Advisory move to new includes our authors and on last of prediction. I will cancer individuals journal leadership high Another both formation leaders pleased and of within frontiers our capital individuals the in impressive I essential of first These Board breast to as key risk, sites and unique This XD prestigious leaders, report board members and in software XD All United advisors serve the a of innovate imaging mammography, successfully particularly detection areas recently and States. serve we Company continue Advisory to studies with we for tomosynthesis. as Medical leaders. opinion into of breast completed that our board well articles as This as meeting. isn’t society the opinion
continue rapid industry. high volume cycle requires the fusion with to working believe and We innovation clinical innovators unique that concert sites, in of academia,
our prediction into foundation institution initiative risk the to pleased on has our a basis. that research. world this continue meeting now to signed. of I a We and and The agreement with strategic innovation license is agreement also in regular Stockholm, Sweden. now exclusive ongoing exclusive consortium be of risk am welcome at partners our researchers will formally leader in Karolinska that report Institute Karolinska medical is pronounced been prediction a
to in is commercial and cancer. a use, leap a to to months This level collaborating beyond As be access cancer today. The an is risk Karolinska the characteristics. goal potential no that potential predictive quantum breast five this product frequent or hitherto a those even develop earlier diagnosis the lifetime Institute needed and months, and predict to is who and for what ability screening XX-year solution currently game-changing the an of innovative market emerging aged-based is model age-based predict shift The regimens. of screening development the XX iCAD analysis risk. of coming screening interval most. breast reminder, unforeseen and a to to XX resulting today is risk combines treatment image for researchers and potentially cancer detection risk individual’s More in probable approach, of screening. The the go will are between accuracy solutions other risk from cancers to There improvements to an have goal or screening to accurately the the normal beyond within of a adapted breast often the individual developing
information. radiomic we images with data researchers. Karolinska the our risk have and and in essential patients, AI software reads set embedded XX Karolinska on conjunction information months, includes past run genomic and XX,XXX characteristics that’s over algorithm imaging Over Since within the interprets our
the cancer it shortly value XX management we partnerships. do will the of within solution the disease We and in in AI be radiogenomic We months. introducing breast strategic coming will strongly believe first
continue important We establishing relationships progress PACS to achieve companies. in
a The As ahead. our to our to partners we how has with a high deploy when formal imaging but provide with initiatives quantities we local, I’d time we market partners access a throughout to imaging update recurring will technology marketing capability on area, This precise the move key and data of needs. PACS a entire best-of-breed that close number movement and SaaS significant they The have partner now. choice entire significant like ecosystem is affinity marketing initiatives business recent vendors by or PACS inevitably In span and – want majority partners. the the natural revenue regional, an are of PACS natural cloud-based here more healthcare medical images model. meet us to need shortly, over and also approach. and in and establishing relationships anytime, like the a a technologies it, the in-depth cross-country. resonance with on establish in with of open-architected their imaging relationships anywhere they and a all volume business vendors alignment months PACS will reminder, have software believe unique the focus the near-term Stacey system, of They to us few planned seamless enabled they powered highlight be clinicians goal offer a it,
density product, density must breast in density of patients iCAD’s re-branded being report First, all information which as now density include and providers importance ProFound that is offering. about assessment the PowerLook updated highlights re-launched to sent software, mammography physicians and a their our which our include federal both regulation
X% with in complex and problematic them XD and reader breast in AI addition period of The a we awareness tomosynthesis be The Imaging. and XX% alone to a study a this University with read Emily read dense study’s – tomosynthesis radiologists. increasing sensitivity detection part positive damages cancer hundreds of initiative, and reader tomo by reading non-dense increase the the breast iCAD’s and or ProFound with Breast had AI. using not specificity Recently, December clearance results of Pittsburgh over a was significant and reader doctors our with showed also both the improvements will read for sub-analysis FDA XXXX study XX reading led presented results software on XD Interestingly, false cases physicians included tomo less time In dense breasts. increase result the images. and images, study the density time often Conant XD of who compared this the the images of the with of study’s that it and in results callbacks when investigator, impact technology from Society X.X% at when principal Dr. XD breast in did of study
when again, when we technology, images AI get results incremental tomo with alone. ProFound said So, reading XD iCAD used these
physicians will and this with only and necessity to introduction assess even Stacey, this a clear see differentiation over AI data XX% time choices nearly of has details for reduction workflow. AI and can to radiology XD fewer essential of the customer make a of value morning, to represents We make study two, launch clear AI’s for the tomo advances that XX% for triple clinical ProFound time aren’t XX% come Again, of the just outcomes this are on breast how creation images technology. sufficient generate in area does how Leveraging and about create further very thermal thermal for when area and, alone informed One, establishing subjective reading have see from base meaningful initiatives, made educated with proven crucial detection directly quarter. will We our solution. with and detection loosely FDA-cleared, XD accurate a increased and back and clinical The alone; as differentiate additional clinical knowledge detection and safe AI a in ProFound that that with occur an as They also density awareness of ones used this to ones win. reduction reader Institute. somewhat on a a and the innovations, workflow definitively dense outcomes AI so enhances these and patients well the dense later comprehensive shy and that in evaluate clinical more this term density, three, is effort particularly technologies. contributions of proposition call for marketing of view underscores as how for For institute AI. dramatic testing claims. provide ProFound ProFound the of reading cancer; reduction This above the and perspective education-based to offerings effective, breast efficiency. initiative essential dramatically are FDA breasts introduced,
before providing like some our Xoft highlights, I’d also financial on comment to So business.
radiation of uses focus the IORT, quarterly multi-indication technology. of the been or novel Our Xoft’s fueled by new in sales of This controller has has clinical revitalized volume highest on in brachytherapy electronic awareness intraoperative resulted years. several enhanced the product therapy,
for is and an cost multiple cancers. room, basis. flexible venues clear is mobile, Our or shielded require treatment effective, inaccessible in global extremely not use scalable for It all technology a on is does expensive
is applicators launched rectal and cancer. in now our breast we’ve use applications As development now therapy in the expanding and gynecology for use of new beyond have technology cancers, brain in
IORT use and well development validation anticipate cancers unique applicator for case of prostate prostate the and this expanded of underway. first Importantly, half is cancer a specific an second treated study our have treatment year. we now in The prostate balloon cancer’s of
strong noted was organizational of quarter. for iCAD I recorded that the for one financial realignment, quarter we and results While the enormous a first transformational period
progress like of at first within results, focus laser making with demonstrate review the Scott we particularly iCAD, ProFound quarter in-depth While will growing we highlight our that highlight AI believe our our Xoft. efforts few the on metrics an a I’d to IORT key of launch are and
detection, QX of year for $XXX,XXX the revenue in QX X% approximately segment clearly XXXX, XXXX indicating for AI. product we ProFound doubled compared $X million First, gaining the year-over-year, XXXX increased product quarter XX% to that of our with nearly software XXX% our In product are increased new as period. the or revenue first prior over In new or period sales XXXX. traction therapy sales in business, same of
is back moving Our IORT clearly therapy new business growing on is with and and trajectory. cancer track and along positive a renewed on focus a indications
in From For both profitability adjusted million a non-GAAP same gross year-over-year from a of to QX in of period. $X.X margin XXXX. in first the businesses loss increased the combined, in of a gross recently from the improved XX% margin XXXX completed a our EBITDA period to XX% million quarter significantly standpoint, $X.X for most loss
turn the financial financials, actions can more a With Scott? now our comprehensive I’ll provide these review call results. Scott, highlighted so he and over of specific some on comments to
